RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone' Sep 11, 2025 08:18AM
Edgewise Therapeutics (EWTX) PT Raised to $49 at RBC Capital Aug 8, 2025 08:43AM
RBC Capital on Edgewise Therapeutics (EWTX): ' We Would Be Buyers on Weakness' Jun 27, 2025 10:36AM
RBC Capital Reiterates Outperform Rating on Edgewise Therapeutics (EWTX) Jun 5, 2025 08:53AM
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 May 14, 2025 08:00AM


Apr 3, 2025 08:52AM RBC Capital on Edgewise Therapeutics (EWTX): 'We See Downside Move As A Buying Opportunity'; PT Lowered
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Sep 20, 2024 06:24AM Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
May 10, 2024 08:00AM Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Apr 22, 2024 06:24AM Edgewise Therapeutics (EWTX) PT Raised to $32 at RBC Capital
May 2, 2023 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 3, 2022 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
Apr 13, 2022 03:58AM UPDATE: RBC Capital Starts Edgewise Therapeutics (EWTX) at Outperform